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ANTIPSYCHOTIC PATTERNS AND TREATMENT COST 
IN FRANCE
Riou-França L1,Westerloppe J2, Launois R1
1REES France, Paris, France; 2Bristol-Myers Squibb, Rueil-Malmaison,
France
OBJECTIVES: There is little knowledge about current antipsy-
chotic usage in France. We describe the new trends in prescrip-
tion and the drug-speciﬁc patient proﬁles. METHODS: A cross
sectional survey was conducted among a sample of ambulatory
and hospital psychiatrists. Psychiatrists registered all schizo-
phrenic patients treated for more than six months during the
month of the study (2741 patients). A more detailed question-
naire was then administered for 1861 patients in 3 speciﬁc treat-
ment categories. This sampling design allows for a sufﬁcient
number of patients within each category. Associations between
treatment prescribed and patient characteristics were explored
using a generalized logit model. RESULTS: Second-Generation
Antipsychotics (SGA’s) are prescribed as the principal treatment
in 62% of the prescriptions. In 78% of prescriptions, only one
antipsychotic is prescribed, associations are more common
among ﬁrst-generation antipsychotics (FGA’s). Olanzapine is the
most prescribed antipsychotic, with a market share of 28%.
There is large variability in dosages. The average daily costs of
treatment (DCT) range from 3.77€ for olanzapine to 0.14€ for
haloperidol. On the whole, the average DCT of a French patient
is of 2.26€. Some co-prescriptions are linked to the principal
treatment, such as antiparkinsonians (related to a prescription of
FGA’s), antidepressives (related to risperidone), anxiolytics
(related to clozapine) and hypnotics (related to amilsupride). Pre-
scription patterns also vary between ambulatory and hospital
psychiatrists; the latter tend to prescribe, among FGA’s, more
long acting forms and, among SGA’s, more clozapine. Ambula-
tory psychiatrists prescribe more non-long acting FGA’s and
more amilsupride. CONCLUSIONS: Introduction of SGA’s in
France has modiﬁed prescribing patterns. These antipsychotics
have a higher DCT. The co-prescriptions vary according to the
antipsychotic prescribed as principal treatment, but the design of
the study does not allow to conclude whether co-prescriptions
are a cause or an effect of the antipsychotic taken.
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WHAT HAPPENS WHEN A PHARMACEUTICAL PRODUCT IS
REMOVED OUT OF REIMBURSEMENT?
Le Pen C
Aremis Consultants and Paris Dauphine University, Paris, France
For cost-containment reasons, French authorities have decided
to remove a large set of pharmaceuticals out of the list of reim-
bursed products. This decision is controversial and the argument
is frequently made that dereimbursed products are largely sub-
stituted by reimbursed more expensive drugs, so that no savings
actually results from that measure. OBJECTIVES: We analyse a
preceding case of product dereimbursement to evaluate this argu-
ment. METHODS: We retrospectively followed a cohort of
patients who received a prescription of a product composed of
omega3 fatty acids in the indication of hypertriglyceridemy. This
drug is no longer reimbursed since September 1998. We collected
prescription data before and after the dereimbursement date. A
“substitution list” including all drugs that can be thought to be
a substitute was established. Finally, all patients were distributed
into three groups, the “continuation group” in which patients
were still treated, the “discontinuation group” in which patients
discontinued their treatment without receiving any product of
the substitution list, and the “substitution group” in which
patients discontinued the treatment but received at least one pre-
scription from the substitution list. Data came from a well
known and reliable physician’s panel. RESULTS: We received a
complete set of data for 1070 patients. The most frequent strat-
egy was the “substitution one” with 41% of patients, 32.5% of
patients simply discontinued their treatment and 26.5% contin-
ued to take the drug. Statins were the most frequent substitution
drugs. Although they were generally more expensive, the
monthly average cost per patient was cut by about 20%. The
real savings were only 70% of the expected savings because of
the substitution strategy. CONCLUSIONS: This dereimburse-
ment decision appeared to be a redistributive game in which the
winners were health insurance and the statins manufacturers and
the losers the manufacturer of the concerned drug and patients
whose out-of-pocket payment increased.
HP6
MODELLING USE OF HOSPITAL SERVICES AS A FUNCTION
OF NEEDS AND SUPPLY IN ITALY
Petrelli A1, Picariello R1, Costa G2
1Piedmont Region, Grugliasco (TO), Italy; 2University of Turin, Italy
OBJECTIVES: To evaluate the role of indirect measures of health
needs in the use of hospital services. METHODS: An ecologic
analysis was conducted in Piedmont region (4000,000 inhabi-
tants in North-West of Italy) using municipality aggregated data
from the health information system and census population. In
order to reduce heterogeneity in dimension of statistical units,
the city of Turin (900,000 inhabitants) was disaggregated by
neighbourhood (n = 23). Linear hierarchical models were applied
to 1.228 statistical units (3528 inhabitants on average) in order
to: 1) take into account the clustered nature of the data; 2) esti-
mate residual variability between local health units (LHU). Stan-
dardized discharge ratios were used as outcome. Direct and
indirect needs measures were taken into account, speciﬁcally:
standardized mortality ratios (SMR) were used as direct measure
of need, while percentages of low educational level, manual
work, rented dwelling, dwelling without indoor bathroom, single
parent households with children, and immigrated people were
used as indirect measures. All the variables were introduced in
the model in a standardized form. In order to take into account
the supply effect on use of health services, number of hospital
beds and distance from the nearest hospital were included. 
Multicollinearity was evaluated using variance inﬂation factor
estimated by standard multivariate linear regression model. Sen-
sitivity analysis was conducted in order to evaluate the effect of
ecologic bias selecting municipality on the basis of demographic
dimension. RESULTS: A positive signiﬁcant relationship was
found for percentage of low educational level (1.38;95%CI:
0.05–2.71) and percentage of rented dwellings (3.19;95%CI:
1.82–4.57). Statistically signiﬁcant coefﬁcients were observed for
distance (negative) and SMR (positive). Residual signiﬁcant vari-
ability between LHU was observed. CONCLUSIONS: These
analysis would like to contribute to a needs-based weighted pop-
ulation for capitation purposes in Italy. The role of geographical
variability in case-mix and endogeneity in the supply should be
better explored.
HP7
STRATEGIES OF PRIORIZATION BASED ON THE SOCIAL
WELFARE FUNCTION
Plans-Rubio P
General Direction of Public Health, Barcelona, Spain
OBJECTIVE: The strategy of priorization based on cost-
effectiveness has been questioned because equity is not taken into
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account. The objective of this study was to develop a strategy of
priorization based on the social welfare function (SWF), and to
apply this method to decide allocation of resources between
smoking cessation therapies and pharmacological treatments of
hypercholesterolemia. METHODS: The social welfare function
relates social welfare to the distribution of health gains between
two patient groups, where the exact form depends on parame-
ter e. The strategy of priorization based on SWF gives a higher
priority to treatments associated with values of e consistent with
that from the SWF. Parameter e of the SWF in Catalonia (Spain)
was determined using multiple logistic regression analysis to
assess preferences concerning the efﬁciency-equity trade-off in a
group of health managers (n = 140). RESULTS: The value of
parameter e obtained was 2.26 (95% CI: 1.07–2.89). This value
was consistent with a non-utilitarian SWF. Values of e obtained
for preventive interventions combining different smoking cessa-
tion methods for smokers and 20–80mg/day lovastatin for indi-
viduals with hypercholesterolemia ranged from 0 to 2.9 in men
and from 0 to 2.4 in women. The intervention using medical
advice for smoking cessation in smokers and 20mg/day lovas-
tatin in individuals with hypercholesterolemia was associated
with an e value of 2.9 in men and 2.4 in women, while inter-
ventions using nicotine substation therapies in smokers were
associated with values of e < 1.0 in men and <0.5 in women.
CONCLUSION: The strategy of priorization based on SWF
gives a higher priority to 20–80mg/day lovastatin for hypercho-
lesterolemia than to nicotine substitution therapies for smokers.
The strategy of priorization based on the SWF could give a
higher priority to new treatments reducing the difference in
health levels between groups of patients.
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EXPLAINING THE LACK OF SUCCESS OF GENERIC DRUGS IN
BELGIUM: A POLICY PERSPECTIVE
Simoens S, Laekeman G
Katholieke Universiteit Leuven, Leuven, Belgium
OBJECTIVES: Whereas the market share held by generic drugs
exceeded 15% in Germany, UK, and Denmark in 2002, this
amounted to 4% in Belgium. This paper purports to review the
policy and regulatory environment surrounding generic drugs in
Belgium with a view to clarifying its low market share.
METHODS: The methodology is based on a literature review
and analysis of legal texts. RESULTS: The low market share held
by generic drugs in Belgium principally derives from the absence
of incentives for physicians to prescribe and for pharmacists to
dispense generic drugs. Although physicians are a major driver
of generic drug use through their prescribing behaviour, they
have no stake in the decision to prescribe original or generic
drugs, and are therefore not cost conscious. Moreover, multi-
plying the number of drugs containing the same active products
confuses the prescribing physician. Belgian pharmacists are not
allowed to substitute generic for original drugs and were, until
recently, ﬁnancially penalized for dispensing generic drugs. Addi-
tionally, marketing too many essentially similar drugs does not
encourage pharmacists to cooperate as their stock gets over-
loaded. Price regulation has stimulated generic drug use, as the
introduction of the reference-based pricing system in 2001 was
associated with an increase in market share of reimbursable
generic drugs by 3%. However, reference pricing also caused a
free fall of prices of original drugs by at least 16%, damaging
one of the driving forces of generic prescribing. CONCLU-
SIONS: If policy makers wish to stimulate generic drug use in
Belgium, they need to recognize the prime role that physicians
and pharmacists play in determining drug use and provide
appropriate incentives. Current initiatives that bring together
health professionals within local intercollegiate networks and
that promote the prescription of drugs using their International
Non-Proprietary Name need to be evaluated.
